Completed OBSERVATIONAL NCT00930319

Effectiveness and Safety of Firmagon® (FAST)

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

Sponsor: Ferring Arzneimittel GmbH

Conditions Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

Interventions Firmagon given by prescription according to SPC

Updated 8 times since 2017 Last updated: Nov 8, 2023 Started: Jun 30, 2009 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, this trial is completed. The trial is conducted by Ferring Arzneimittel GmbH and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2023 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2023 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Arzneimittel GmbH
Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalen, Germany , Abensberg, Germany , Ahaus, Germany , Ahrensburg, Germany , Alsdorf, Germany , Alsfeld, Germany , Altenburg, Germany , Andernach, Germany , Ansbach, Germany , Augsburg, Germany and 167 more locations